Recce Ltd has released a press release.
Positive Ph I/II DFI Efficacy Data to Support Site Expansion
Filed with ASX ·
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Murdoch Children's R327 Efficacy UTI in-vivo
- RCE Awarded Further $11.17m Advanced Overseas Finding
- RCE Awarded $43.7m AusIndustry Advanced Overseas Finding
- Murdoch Children's R327 Efficacy N.gonorrhoeae in-vivo
- Canadian Patent Granted for RECCE Anti-Infectives
Later from Recce Pharmaceuticals
- RCE Establishes Strategic Partnership in South-East Asia
- Safety Committee Approves Expansion of Ph I/II DFI Trial
- Recce Receives AUD $11.17m R&D Advance
- Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
- Patent Granted in Israel for RECCE Anti-Infectives
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals